CUPERTINO, Calif. – NextBio, provider of an innovative platform that enables life science researchers to search, discover, and share knowledge locked within public and proprietary data, announced that Sanford-Burnham Medical Research Institute has renewed and expanded its license to NextBio Enterprise. The new agreement both expands the Institute’s user-base for NextBio and adds access to the Sequence-Centric Module that enables the exploration and utilization of massive amounts of public and internally generated sequencing data. NextBio Enterprise with the Sequence Centric Module allows organizations to create corporate-wide genomic data platforms to serve the needs of their global research teams.

“As an organization whose mission is understanding disease at the molecular level, NextBio has become an essential tool for the Stanford-Burnham Medical Research Institute’s scientific efforts, enabling our researchers to quickly examine and understand their data in the context of huge quantities of information from both Institute studies and public research worldwide,” said Dr. Craig Hauser, Vice President for Scientific Resources. “Three years of experience in using NextBio has convinced us of its strong value to our work, and we look forward to giving our scientists increased ability to examine diverse data using a single research platform through the NextBio Sequence-Centric Module.”

“Sanford-Burnham Medical Research Institute has been a pioneering user and supporter of NextBio since our earliest days and has repeatedly expanded its license and access to NextBio as we have added new capabilities to our research platform,” said Saeid Akhtari, NextBio President and Chief Executive Officer. “We are very pleased to see that the Institute has made NextBio Enterprise an integral part of its research efforts to generate hypotheses, design experiments, and, ultimately, make major discoveries.”

About Sanford-Burnham Medical Research Institute

Sanford-Burnham Medical Research Institute is dedicated to discovering the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. Sanford-Burnham, with operations in California and Florida, is one of the fastest-growing research institutes in the country. The Institute ranks among the top independent research institutions nationally for NIH grant funding and among the top organizations worldwide for its research impact. From 1999 – 2009, Sanford-Burnham ranked #1 worldwide among all types of organizations in the fields of biology and biochemistry for the impact of its research publications, defined by citations per publication, according to the Institute for Scientific Information. According to government statistics, Sanford-Burnham ranks #2 nationally among all organizations in capital efficiency of generating patents, defined by the number of patents issued per grant dollars awarded.

Sanford-Burnham utilizes a unique, collaborative approach to medical research and has established major research programs in cancer, neurodegeneration, diabetes, and infectious, inflammatory, and childhood diseases. The Institute is especially known for its world-class capabilities in stem cell research and drug discovery technologies. Sanford-Burnham is a nonprofit public benefit corporation. For more information, please visit www.sanfordburnham.org.

About NextBio

NextBio is the provider of an innovative platform that enables life science researchers to search, discover, and share knowledge locked within public and proprietary data. NextBio’s platform seamlessly combines powerful tools with unique correlated content to transform information into knowledge, providing the foundation for new scientific discoveries. NextBio’s unique ‘correlation engine’ pre-computes billions of significant connections among public and private data and enables researchers to intelligently mine it in real-time. NextBio helps organizations increase productivity and dramatically improve collaboration across therapeutic groups and geographic boundaries. NextBio is delivered as a SaaS (Software as a Service) solution resulting in quick deployment and rapid return on investment.

Today, NextBio is used by researchers at the world’s top commercial and academic institutions. NextBio’s enterprise solution has been deployed at Burnham Institute for Medical Research, Celgene, Eli Lilly, Genzyme, Johnson & Johnson, Merck, Regeneron, Scripps Research Institute, Stanford University, UCB, and Takeda, among many others. To learn more about NextBio, please visit our website at https://www.nextbio.com.